Atara Biotherapeutics Dirección

Dirección controles de criterios 2/4

Atara Biotherapeutics' El consejero delegado es Pascal Touchon , nombrado en Jun 2019, tiene un mandato de 4.67 años. la remuneración anual total es $5.16M , compuesta por 13.9% salario y 86.1% primas, incluidas acciones y opciones de la empresa. posee directamente 0.26% de las acciones de la empresa, por valor de €205.36K . La antigüedad media del equipo directivo y del consejo de administración es de 3.5 años y 8.3 años respectivamente.

Información clave

Pascal Touchon

Chief Executive Officer (CEO)

US$5.2m

Compensación total

Porcentaje del salario del CEO	13.9%
Permanencia del CEO	4.8yrs
Participación del CEO	0.2%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	8.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pascal Touchon en comparación con los beneficios de Atara Biotherapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$276m
Sep 30 2023	n/a	n/a	-US$286m
Jun 30 2023	n/a	n/a	-US$305m
Mar 31 2023	n/a	n/a	-US$215m
Dec 31 2022	US$5m	US$718k	-US$228m
Sep 30 2022	n/a	n/a	-US$247m
Jun 30 2022	n/a	n/a	-US$248m
Mar 31 2022	n/a	n/a	-US$350m
Dec 31 2021	US$5m	US$681k	-US$340m
Sep 30 2021	n/a	n/a	-US$328m
Jun 30 2021	n/a	n/a	-US$318m
Mar 31 2021	n/a	n/a	-US$311m
Dec 31 2020	US$5m	US$655k	-US$307m
Sep 30 2020	n/a	n/a	-US$304m
Jun 30 2020	n/a	n/a	-US$301m
Mar 31 2020	n/a	n/a	-US$298m
Dec 31 2019	US$7m	US$319k	-US$291m

Compensación vs. Mercado: Pascal($USD5.16M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD414.42K).

Compensación vs. Ingresos: Pascalha aumentado mientras la empresa no es rentable.

CEO

Pascal Touchon (60 yo)

4.8yrs

Permanencia

US$5,158,128

Compensación

Dr. Pascal Touchon, D.V.M., serves as Independent Director at Ipsen S.A. since October 4, 2023. He has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 201...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pascal Touchon	President	4.8yrs	US$5.16m	0.25% $ 182.8k
K. Murugan	Executive VP & Chief Legal Officer	4yrs	US$1.79m	0.091% $ 67.7k
Eric Hyllengren	Executive VP & Chief Financial Officer	less than a year	sin datos	0.065% $ 48.1k
Anhco Nguyen	Executive VP and Chief Scientific & Technical Officer	2.9yrs	sin datos	0.069% $ 51.3k
Alex Chapman	Vice President of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Jill Henrich	Executive VP and Global Head of Regulatory Affairs & Quality	4.3yrs	sin datos	0.043% $ 32.0k
Dan Maziasz	Executive VP & Chief Business Officer	3.3yrs	sin datos	sin datos
Rajani Dinavahi	Senior VP & Chief Medical Officer	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: AT2El equipo directivo de la empresa se considera experimentado (3.5 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pascal Touchon	President	4.8yrs	US$5.16m	0.25% $ 182.8k
Eric Dobmeier	Independent Director	9.1yrs	US$370.35k	0.42% $ 314.2k
William Heiden	Independent Director	8.4yrs	US$355.35k	0.13% $ 94.3k
Matthew Fust	Independent Director	10.1yrs	US$370.35k	0.044% $ 32.3k
Carol Gallagher	Chairman & Lead Independent Director	11.3yrs	US$357.85k	0.35% $ 262.2k
Ameet Mallik	Independent Director	2.7yrs	US$345.35k	0.017% $ 12.7k
Maria Roncarolo	Independent Director	3.9yrs	US$345.35k	0.026% $ 19.5k

8.4yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: La junta directiva de AT2 se considera experimentada (8.3 años de antigüedad promedio).

Atara Biotherapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Independent Director recently bought €95k worth of stock

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Recent updates

Full year 2023 earnings released: US$2.61 loss per share (vs US$2.24 loss in FY 2022)

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Independent Director recently bought €95k worth of stock

New minor risk - Market cap size

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released: US$0.66 loss per share (vs US$0.82 loss in 3Q 2022)

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Revenue and earnings growth

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

President recently sold €56k worth of stock

Atara Biotherapeutics, Inc. Announces Executive Changes

Full year 2022 earnings released: US$2.24 loss per share (vs US$3.63 loss in FY 2021)

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Third quarter 2022 earnings released: US$0.82 loss per share (vs US$0.91 loss in 3Q 2021)

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Atara Biotherapeutics, Inc. Announces Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expanded Access Program (EAP) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and Update on Tab-cel EMA Regulatory Progress

Atara Biotherapeutics Provides Update on Strategic Collaboration with Bayer

Atara and MSK Expects to Provide A Phase 1 Data Update for Ata2271 in Second Half 2022

Atara Biotherapeutics, Inc. Names Charlene Banard as Chief Technical Officer

Atara Biotherapeutics, Inc. Provides Update on ATA2271 Autologous CAR T Trial

Atara Biotherapeutics, Inc. to Report Fiscal Year 2021 Results on Feb 28, 2022

FUJIFILM Diosynth Biotechnologies California, Inc. entered into an asset purchase agreement to acquire T-Cell Operations and Manufacturing Facility in Thousand Oaks, California from Atara Biotherapeutics, Inc. (NasdaqGS:ATRA) for $100 million.

Atara Biotherapeutics, Inc. Lauds the Second High Impact Study This Month Solidifying EBV as the Primary Driver of the Development of MS

Atara Biotherapeutics, Inc. to Complete the Biologics License Application for Patients with EBV+ PTLD in Second Quarter of 2022

Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting

Atara Biotherapeutics, Inc. Announces New Preclinical and Preliminary Clinical Results for ATA2271 at ESMO Immuno-Oncology Congress 2021

Atara Biotherapeutics, Inc. Announces That the Marketing Authorization Application for Tabelecleucel (Tab-Cel®) Has Been Fully Validated by the European Medicines Agency

European Medicines Agency Grants Atara Biotherapeutics Accelerated Assessment of Tab-Cel® for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Ptld)

High number of new directors

Atara Biotherapeutics Announces Operational Progress on Tabelecleucel (Tab-Cel®) for Post-Transplant Lymphoproliferative Disease (PTLD)

SVP & Chief Commercial Officer recently bought €413k worth of stock

Atara Biotherapeutics Presents Positive Tab-Cel Long-Term Overall Survival Data for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease After Solid Organ Transplant at ATC 2021 Virtual Connect

Atara Biotherapeutics Presents New Long-Term Overall Survival Data from A Combined Analysis of Phase 2 Tab-Cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease At the Ebmt 2021 Annual Meeting

Atara Biotherapeutics, Inc. Reports Operational Progress

New 90-day low: €13.90

Atara Biotherapeutics, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience

Atara Biotherapeutics Provides Regulatory Update for Tab-Cel(R) for Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $174.999792 million.

Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219 at the 62 American Society of Hematology Annual Meeting

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

New 90-day high: €22.04

New 90-day high: €15.35

Atara Biotherapeutics, Inc. Presents New Preclinical Data on ATA3271 at the 35th Society for Immunotherapy of Cancer Annual Meeting (SITC 2020)

Atara Biotherapeutics, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Atara Biotherapeutics, Inc. to Report Q2, 2020 Results on Aug 05, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación